vs

Side-by-side financial comparison of H&R BLOCK INC (HRB) and Tarsus Pharmaceuticals, Inc. (TARS). Click either name above to swap in a different company.

H&R BLOCK INC is the larger business by last-quarter revenue ($198.9M vs $151.7M, roughly 1.3× Tarsus Pharmaceuticals, Inc.). Tarsus Pharmaceuticals, Inc. runs the higher net margin — -5.5% vs -121.8%, a 116.3% gap on every dollar of revenue. On growth, Tarsus Pharmaceuticals, Inc. posted the faster year-over-year revenue change (128.4% vs 11.1%). Tarsus Pharmaceuticals, Inc. produced more free cash flow last quarter ($13.0M vs $-649.5M). Over the past eight quarters, Tarsus Pharmaceuticals, Inc.'s revenue compounded faster (134.4% CAGR vs -69.8%).

H&R Block, Inc., or H&R Block, is an American tax preparation company operating in Canada, the United States, and Australia. The company was founded in 1955 in Kansas City, Missouri, by brothers Henry W. Bloch and Richard Bloch.

Tarsus Pharmaceuticals, Inc. is a late-stage clinical biopharmaceutical company focused on developing and commercializing innovative therapeutic candidates for unmet medical needs in ophthalmology, dermatology, and other specialty care areas. It operates primarily in the United States, with lead product candidates targeting common, underdiagnosed conditions including demodex blepharitis and rosacea.

HRB vs TARS — Head-to-Head

Bigger by revenue
HRB
HRB
1.3× larger
HRB
$198.9M
$151.7M
TARS
Growing faster (revenue YoY)
TARS
TARS
+117.3% gap
TARS
128.4%
11.1%
HRB
Higher net margin
TARS
TARS
116.3% more per $
TARS
-5.5%
-121.8%
HRB
More free cash flow
TARS
TARS
$662.5M more FCF
TARS
$13.0M
$-649.5M
HRB
Faster 2-yr revenue CAGR
TARS
TARS
Annualised
TARS
134.4%
-69.8%
HRB

Income Statement — Q2 FY2026 vs Q4 FY2025

Metric
HRB
HRB
TARS
TARS
Revenue
$198.9M
$151.7M
Net Profit
$-242.2M
$-8.4M
Gross Margin
Operating Margin
-160.5%
-5.3%
Net Margin
-121.8%
-5.5%
Revenue YoY
11.1%
128.4%
Net Profit YoY
0.5%
63.8%
EPS (diluted)
$-0.17

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
HRB
HRB
TARS
TARS
Q4 25
$198.9M
$151.7M
Q3 25
$203.6M
$118.7M
Q2 25
$1.1B
$102.7M
Q1 25
$2.3B
$78.3M
Q4 24
$179.1M
$66.4M
Q3 24
$193.8M
$48.1M
Q2 24
$1.1B
$40.8M
Q1 24
$2.2B
$27.6M
Net Profit
HRB
HRB
TARS
TARS
Q4 25
$-242.2M
$-8.4M
Q3 25
$-165.8M
$-12.6M
Q2 25
$299.4M
$-20.3M
Q1 25
$722.3M
$-25.1M
Q4 24
$-243.4M
$-23.1M
Q3 24
$-172.6M
$-23.4M
Q2 24
$257.8M
$-33.3M
Q1 24
$690.7M
$-35.7M
Gross Margin
HRB
HRB
TARS
TARS
Q4 25
Q3 25
Q2 25
Q1 25
57.4%
Q4 24
Q3 24
Q2 24
Q1 24
57.6%
Operating Margin
HRB
HRB
TARS
TARS
Q4 25
-160.5%
-5.3%
Q3 25
-106.3%
-12.2%
Q2 25
33.1%
-21.6%
Q1 25
42.1%
-33.5%
Q4 24
-174.4%
-36.8%
Q3 24
-119.8%
-52.3%
Q2 24
33.0%
-81.6%
Q1 24
41.5%
-136.5%
Net Margin
HRB
HRB
TARS
TARS
Q4 25
-121.8%
-5.5%
Q3 25
-81.5%
-10.6%
Q2 25
27.0%
-19.8%
Q1 25
31.7%
-32.1%
Q4 24
-135.9%
-34.8%
Q3 24
-89.0%
-48.7%
Q2 24
24.3%
-81.6%
Q1 24
31.6%
-129.4%
EPS (diluted)
HRB
HRB
TARS
TARS
Q4 25
$-0.17
Q3 25
$-0.30
Q2 25
$-0.48
Q1 25
$5.31
$-0.64
Q4 24
$-0.57
Q3 24
$-0.61
Q2 24
$-0.88
Q1 24
$4.86
$-1.01

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
HRB
HRB
TARS
TARS
Cash + ST InvestmentsLiquidity on hand
$349.2M
$417.3M
Total DebtLower is stronger
$2.4B
$72.4M
Stockholders' EquityBook value
$-823.1M
$343.4M
Total Assets
$2.9B
$562.2M
Debt / EquityLower = less leverage
0.21×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
HRB
HRB
TARS
TARS
Q4 25
$349.2M
$417.3M
Q3 25
$376.4M
$401.8M
Q2 25
$983.3M
$381.1M
Q1 25
$772.9M
$407.9M
Q4 24
$320.1M
$291.4M
Q3 24
$415.9M
$317.0M
Q2 24
$1.1B
$323.6M
Q1 24
$794.6M
$298.5M
Total Debt
HRB
HRB
TARS
TARS
Q4 25
$2.4B
$72.4M
Q3 25
$1.7B
$72.3M
Q2 25
$1.1B
$72.1M
Q1 25
$1.1B
$72.0M
Q4 24
$1.9B
$71.8M
Q3 24
$1.5B
$71.7M
Q2 24
$1.5B
$71.6M
Q1 24
$1.5B
$29.9M
Stockholders' Equity
HRB
HRB
TARS
TARS
Q4 25
$-823.1M
$343.4M
Q3 25
$-550.9M
$335.1M
Q2 25
$88.9M
$332.6M
Q1 25
$-192.8M
$342.5M
Q4 24
$-872.5M
$224.5M
Q3 24
$-368.1M
$237.5M
Q2 24
$90.6M
$252.2M
Q1 24
$-129.8M
$275.2M
Total Assets
HRB
HRB
TARS
TARS
Q4 25
$2.9B
$562.2M
Q3 25
$2.6B
$534.6M
Q2 25
$3.3B
$495.0M
Q1 25
$3.2B
$500.8M
Q4 24
$2.7B
$377.0M
Q3 24
$2.5B
$376.3M
Q2 24
$3.2B
$376.8M
Q1 24
$3.2B
$349.3M
Debt / Equity
HRB
HRB
TARS
TARS
Q4 25
0.21×
Q3 25
0.22×
Q2 25
12.86×
0.22×
Q1 25
0.21×
Q4 24
0.32×
Q3 24
0.30×
Q2 24
16.46×
0.28×
Q1 24
0.11×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
HRB
HRB
TARS
TARS
Operating Cash FlowLast quarter
$-614.0M
$19.3M
Free Cash FlowOCF − Capex
$-649.5M
$13.0M
FCF MarginFCF / Revenue
-326.6%
8.6%
Capex IntensityCapex / Revenue
17.9%
4.2%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$524.1M
$-22.3M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
HRB
HRB
TARS
TARS
Q4 25
$-614.0M
$19.3M
Q3 25
$-356.8M
$18.3M
Q2 25
$251.6M
$-29.4M
Q1 25
$1.3B
$-20.7M
Q4 24
$-567.1M
$-22.2M
Q3 24
$-328.6M
$-8.7M
Q2 24
$300.6M
$-14.4M
Q1 24
$1.4B
$-37.8M
Free Cash Flow
HRB
HRB
TARS
TARS
Q4 25
$-649.5M
$13.0M
Q3 25
$-370.0M
$16.3M
Q2 25
$241.3M
$-30.4M
Q1 25
$1.3B
$-21.2M
Q4 24
$-597.4M
$-22.3M
Q3 24
$-347.3M
$-8.9M
Q2 24
$290.7M
$-15.4M
Q1 24
$1.3B
$-38.0M
FCF Margin
HRB
HRB
TARS
TARS
Q4 25
-326.6%
8.6%
Q3 25
-181.8%
13.8%
Q2 25
21.7%
-29.6%
Q1 25
57.2%
-27.1%
Q4 24
-333.6%
-33.5%
Q3 24
-179.2%
-18.6%
Q2 24
27.4%
-37.8%
Q1 24
61.4%
-137.5%
Capex Intensity
HRB
HRB
TARS
TARS
Q4 25
17.9%
4.2%
Q3 25
6.5%
1.6%
Q2 25
0.9%
1.0%
Q1 25
1.0%
0.8%
Q4 24
17.0%
0.1%
Q3 24
9.7%
0.6%
Q2 24
0.9%
2.5%
Q1 24
1.0%
0.6%
Cash Conversion
HRB
HRB
TARS
TARS
Q4 25
Q3 25
Q2 25
0.84×
Q1 25
1.83×
Q4 24
Q3 24
Q2 24
1.17×
Q1 24
1.97×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons